A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 3110A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 19 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Feb 2015 New trial record